REG - Angle PLC - Board Changes

AngleAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250912:nRSL0495Za&default-theme=true

RNS Number : 0495Z  Angle PLC  12 September 2025

 For immediate release  12 September 2025

 

ANGLE plc ("the Company")

 

BOARD CHANGES

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, announces that, following feedback and
discussions with a significant shareholder, Andrew Newland, Chief Executive,
and Ian Griffiths, Finance Director, have agreed to step down from their
positions on the Board.

 

They remain committed and supportive of the Company and intend to support the
Company with an orderly handover.

 

The Board now comprises Dr. Jan Groen, Non-executive Chairman, and Dr. Joseph
Eid, Non-executive Director.  It is proposed that the Board be expanded in
due course.

 

 

For further information:

 

 ANGLE plc                                       +44 (0) 1483 343434
 Dr. Jan Groen, Non-executive Chairman           j.groen@angleplc.com

 Dr. Joseph Eid, Non-executive Director

 Cavendish (NOMAD and Broker)                    +44 (0) 20 7220 0500

 Geoff Nash / Isaac Hooper (Corporate Finance)

 Sunila de Silva (Corporate Broking)

 Nigel Birks (Life Science Specialist Sales)

 FTI Consulting

 Simon Conway, Ciara Martin, Sam Purewal         +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                        +1 (212) 850 5624

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://protect.checkpoint.com/v2/r01/___https:/angleplc.com/investor-relations/glossary/___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6bzo0NWNkOTlkNDliOTlmNDBjMjE5MmQyMjYwODBkNjJjMDo3OjYwOTM6MDNiYTZjZjg5YTJiZGQ1NGE4YjNhYjdkNzkxZWMyZDQzNTcxNmVjNTllMzdjMTY5NDMzZDgyMGMzMjgxMjliYTpwOlQ6Tg)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 System enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system, associated
consumables and assays. The clinical services business is offered through
ANGLE's GCLP-compliant laboratories.  Services include custom made assay
development and clinical trial testing for pharma.

 

Over 115 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(https://protect.checkpoint.com/v2/r01/___http:/www.angleplc.com___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6bzo0NWNkOTlkNDliOTlmNDBjMjE5MmQyMjYwODBkNjJjMDo3OmI1YTc6MTFiNjRjMDZiNjQ0YWI4ZDA4OGQ1ZDVjN2FjNzU4YTQzMWY3ZmE1MjliYmQzNWYwMTM3YTY1ZGZhODI0MGY0MDpwOlQ6Tg)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPKDBQDBKBCCD